Can we create cures faster?
I believe the answer is a definitive yes we can!
The bottleneck is the thousands of fiercely competitive pharmaceutical and device manufacturers inundating the clinical trial system which is governed by Institutional Review Boards or (IRB’s). Absent an electronic standard, IRB’s have resorted to the lowest common denominator of manual review of paper forms.
Expensive proprietary solutions have failed to achieve critical mass. Successful trials are indeed slowed by this inefficiency and failed trials are often neither identified early enough to minimize harmful, sometimes deadly, adverse events to patients nor timely ended to make way for new trials and, perhaps, the next major cure.
I know it is a big idea, but let’s forge an open approach project to facilitate the collaborative creation, peer-review, resourcing, execution and sharing of outcomes-based programs for global good.
Introducing CyberMedica
The CyberMedica Suite of software products is in the process of being designed in uml (http://uml.cybermedica.org/) to run on an application service provider platform as a software as a service offering.
In the creation of CyberMedica we have developed a comprehensive Systems Development Life Cycle (http://sdlc.cybermedica.org/) comprised of rights, roles, responsibilities, swim lane diagrams and project templates for all of the internal policies, processes and procedures including development and infrastructure engineering of the technology platform.
Additionally, delivery organization service level agreements and strategic customer centric product roadmaps have been documented and integrated to ISO levels of quality and process and peer-reviewed by EMC, Cisco, Oracle and Microsoft.
The Vision
A long held vision for equitable ethical democratization of technologies is what drives the culture embodied and envisioned in the CyberMedica Project.
Any and all of the missions, goals, programmes, policies, processes, procedures, developments, roadmaps shall be governed by the system itself ensuring collaboration, ethical decisioning, peer-review, outcomes based metrics and proactive transparency.
All participation shall be voluntary and as that of a sovereign individual. As such each and every contribution shall be attributed to that member. All rights for such contributions shall be considered shared with CyberMedica for commerce and free attribution share alike for the greater public good under the Creative Commons Non-Commercial Attribution Share Alike license and Science Commons approach.
To the extent that CyberMedica licenses contributed works for commercial purposes a mechanism shall exist to directly attribute the direct end-user value attributable to contributions of every sovereign and an equitable portion of such derived value as captured by license revenues shall be paid to the sovereign and his or her heirs in perpetuity.
